Pharming Group and Santarus have filed a biologics license application with the FDA for approval to use Ruconest, a recombinant human C1 esterase inhibitor, as a treatment for acute angioedema attacks in people with hereditary angioedema. Santarus holds the right to market the drug in North America.

Related Summaries